Can cholera vaccine reduce the risk of death in colorectal cancer patients?

Share This Post

A Swedish study showed that vaccination with cholera after diagnosis of colorectal cancer can reduce the risk of colorectal cancer-related death and all-cause mortality. (Online version of Gastroenterology September 15, 2017).

This should be the first national population-based study to explore the relationship between vaccination with cholera after diagnosis of colorectal cancer and the risk of death. Previous studies have shown that the cholera vaccine may have multiple effects in regulating the body’s immune system and may also reduce the formation of colon polyps in mouse models.

The researchers believe that colorectal cancer is more common in developed countries than in developing countries. Perhaps less exposure to microbes in childhood is also associated with an increased risk of developing colorectal cancer in adulthood.

The researchers used the Swedish National Cancer Registration and Prescription Drug Registration Database to retrospectively analyze the data of 175 patients who received cholera vaccine after diagnosis of colorectal cancer from mid-2005 to 2012. As for the reason why the cholera vaccine is unknown, it may be that patients need to travel to other countries.

The analysis showed that compared with patients who were not vaccinated with cholera (525 patients), patients who received cholera vaccine after diagnosis of colorectal cancer had a 47% lower risk of colorectal cancer death and a 41% overall risk of death. This survival advantage exists in patients with different ages, genders, and stages of colorectal cancer at diagnosis.

The researchers hypothesized that the cholera vaccine may play a role in inhibiting the progression of colorectal cancer by stimulating immune cells such as CD8 positive T cells, macrophages and NK cells, and / or by affecting the expression of genes related to tumorigenesis. The researchers believe that if the results of these studies can be verified in other population-based studies or randomized clinical studies, then the use of cholera vaccine for adjuvant treatment of colorectal cancer is not impossible.

Researchers studying microbial infections and tumors have pointed out that more and more research evidence supports that microbes or their products can stimulate the body’s immune system and bring health benefits for the protection of certain types of tumors and immune-related diseases However, the improvement of sanitary conditions makes us less and less likely to obtain a healthy immune system caused by microbial exposure. A safe oral vaccine that can enhance immune function may bring us significant health benefits. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy